Consistent with the ELISA results, confocal images showed that the repebody rEgH9 can specifically recognize target cancer cells in an EGFR-dependent manner (Figure 2D) and revealed that the repebody with a smaller KD value has a higher binding ability to target antigens displayed on the tumor cell surface (Figure S5). The gene discussed is EGFR; the disease is neoplasm.